文献速递细胞病理与分子病理

分级细胞学诊断报告系统在不确定浆膜腔积液恶性风险中的价值

The value of a tiered cytology diagnostic reporting system in assessing the risk of malignancy in indeterminate serous effusions.
PubMed 文献 · Cancer Cytopathol · 2020-08-18

该研究回顾性分析了1年内报告的145例AUS和98例SFM浆膜腔积液病例,基于随访结果计算恶性风险(ROM)。AUS组69例有随访,ROM为39%;SFM组61例有随访,ROM为64%,两组差异有统计学意义(P < .01),支持将AUS和SFM作为独立诊断类别。

要点

  • SFM组恶性风险(64%)显著高于AUS组(39%),P < .01。
  • AUS用于细胞缺乏定量和/或形态学特征以明确诊断时。
  • SFM用于细胞形态可疑恶性但稀少,无法行免疫组化或流式细胞术时。

核心结论

  • SFM的恶性风险显著高于AUS(P < .01),支持将两者作为独立诊断类别。

研究设计与样本

  • 回顾性分析1年内报告的145例AUS和98例SFM浆膜腔积液(胸膜、腹膜、心包)病例,基于同一部位既往和/或后续积液和/或组织活检确诊恶性肿瘤计算ROM。

主要发现

  • AUS组69例有随访结果,ROM为39%。
  • SFM组61例有随访结果,ROM为64%。
  • AUS组中15%(n=22)的病例进行了免疫组化或流式细胞术,结果均不明确。
  • SFM组中64%(n=63)因细胞稀少无法行免疫组化或流式细胞术,36%(n=35)结果不明确。

关键数值与推荐

  • AUS类别用于细胞缺乏明确诊断所需的定量(细胞数量)和/或定性(形态学)特征时。
  • SFM类别用于细胞形态可疑恶性但稀少,无法行免疫组化或流式细胞术,或结果不明确时。

临床怎么用

  • 在浆膜腔积液细胞学报告中采用AUS和SFM分级术语,有助于区分恶性风险。
  • SFM组恶性风险较高,应密切结合临床和影像学随访。
  • AUS组恶性风险中等,需结合免疫组化或流式细胞术等辅助检查进一步评估。

局限性

  • 回顾性研究,仅基于单中心1年数据。
  • 部分病例缺乏随访结果,ROM计算基于可用随访病例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The International System for Reporting Serous Fluid Cytopathology was recently proposed as a tiered structure to provide consistent reporting terminology for serous effusions. Because of the variation in reporting practices for indeterminate serous effusions, namely, the atypia of undetermined significance (AUS) and suspicious for malignancy (SFM) groups, the authors retrospectively reviewed cases in these 2 categories at their institution and determined the associated risk of malignancy (ROM). METHODS: Pleural, peritoneal, and pericardial effusions that were reported as AUS or SFM over a 1-year period were reviewed, and their associated ROMs were calculated based on confirmation of malignancy by previous and/or subsequent fluid and/or tissue biopsy specimens from the same general location. RESULTS: In total, 145 AUS and 98 SFM serous effusion cases were identified. The AUS category was used when the cells in question lacked the requisite quantitative (cell number) and/or qualitative (morphologic) features for a definitive diagnosis. Immunohistochemistry (IHC) or flow cytometry (FCM) was available in 15% of cases (n = 22) with inconclusive results. The ROM based on 69 cases with available follow-up results was 39%. In contrast, the SFM category demonstrated cells that were morphologically suspicious for malignancy but sparse, precluding IHC or FCM (n = 63; 64%) or yielding inconclusive results (n = 35; 36%). The ROM in the SFM category, based on follow-up results of 61 cases, was 64%. CONCLUSIONS: The ROM for SFM was significantly higher than that for AUS (P < .01), supporting separate diagnostic categories for these 2 groups.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Hou T, Landon G, Stewart J, et al. The value of a tiered cytology diagnostic reporting system in assessing the risk of malignancy in indeterminate serous effusions. Cancer Cytopathol. 2020. PMID: 32809259. doi:10.1002/cncy.22345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。